Loading organizations...
Develops FIDA technology for in-solution biophysical analysis of proteins and nanoparticles for drug development and research.
Based in Søborg, Denmark, Fida Biosystems develops proprietary Flow Induced Dispersion Analysis technology for the in-solution biophysical analysis of proteins and nanoparticles. The Danish enterprise manufactures and sells these specialized instruments to pharmaceutical companies, biotechnology researchers, and academic institutions to quantify molecular interactions, particle sizes, and structural changes during drug development. To date, Fida Biosystems has sold over 100 instruments to laboratories worldwide, contributing to the company doubling its annual revenue over the past year. The organization recently secured a €5 million Series A funding extension from a syndicate of venture investors that includes EIFO, Vækstfonden, and Fåhraeus Startup and Growth Fund. Furthermore, the firm filed a new patent for determining molecular interaction properties and established a strategic technology collaboration with Cytiva. Fida Biosystems was founded in 2013 by Henrik Jensen, Jesper Østergaard, and Brian Sørensen.
Fida Biosystems has raised $5.9M across 1 funding round.
Fida Biosystems has raised $5.9M in total across 1 funding round.
Fida Biosystems has raised $5.9M in total across 1 funding round.
Fida Biosystems's investors include Linus Wiebe, Tonni Bülow-Nielsen.
Fida Biosystems has raised $5.9M across 1 funding round. Most recently, it raised $5.9M Series A Extension in December 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 16, 2025 | $5.9M Series A Extension | Linus Wiebe | Tonni Bülow-Nielsen |